LNTH-2403
/ Lantheus
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 18, 2026
Mass dose effects of the immunotheranostic [89Zr]Zr-LNTH-2403 by PET/CT and dosimetry in non-human primates
(AACR 2026)
- "These findings demonstrate a favorable safety and dosimetry profile for [89Zr] Zr-LNTH-2403 in NHPs, supporting its advancement toward first-in-human imaging studies. Importantly, the administered mass of mAb significantly affected the radiotracer's blood and normal organ biodistribution, highlighting the value of preclinical mass-dose optimization in humans."
First-in-human • Oncology • Solid Tumor • LRRC1
February 10, 2026
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
(clinicaltrials.gov)
- P1/2 | N=55 | Recruiting | Sponsor: Lantheus Medical Imaging | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Osteosarcoma • Sarcoma • Solid Tumor
January 23, 2026
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
(clinicaltrials.gov)
- P1/2 | N=55 | Not yet recruiting | Sponsor: Lantheus Medical Imaging
New P1/2 trial • Oncology • Osteosarcoma • Sarcoma • Solid Tumor
December 10, 2025
DUNP19: A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
(clinicaltrials.gov)
- P1 | N=16 | Not yet recruiting | Sponsor: Radiopharm Theranostics, Ltd
New P1 trial • Breast Cancer • Colorectal Cancer • Head and Neck Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer
1 to 4
Of
4
Go to page
1